Promising pipeline drugs to transform Fragile X Syndrome treatment market by 2030: GlobalData Read more
Less than five per cent of adults with overactive bladder currently treated with drug therapies: GlobalData Read more
Zydus Cadila Desidustat’s better positioned to get first-to-market advantage within HIF-PHI class in India, says GlobalData Read more